Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Nigel J BundredNuria PortaAdrian Murray BruntAngela CramerAndrew HanbyAbeer M ShaabanEmad A RakhaAnne C ArmstrongRamsey I CutressDavid DodwellMarie A EmsonAbigail EvansSue M HartupKieran HorganSarah E MillerStuart A McIntoshJames P MordenJay NaikSankaran NarayananJane OoiAnthony I SkeneDavid A CameronJudith M BlissPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Early response after short duration anti-HER2 dual therapy identifies cancers dependent on the HER2 pathway providing a strategy for exploring risk-adapted individualized treatment de-escalation.